secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001558370-24-007596
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Q1 net revenue $144.9M, GAAP net income $27.7M, CEO steps down May 24
-------------------------------------------------------------------------------

- GAAP net income of $27.7M ($0.71 diluted EPS) vs. loss of $(17.4M) in Q1 2023.
- Adjusted EBITDA of $92.4M, up 5% YoY; non-GAAP adjusted EPS of $1.45.
- Record Belbuca revenue of $50.7M, up 15% YoY; total prescriptions up 4.2%.
- CEO Joe Ciaffoni to step down May 24, 2024; Michael Heffernan named interim CEO.
- Board authorized $35M accelerated share repurchase program; reiterated FY2024 guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000155837024007596/0001558370-24-007596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000155837024007596/coll-20240509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer